Cloudian Appoints Hamed Fadel as VP Customer Success to Build on Company's Stellar Record of Service and Support
SAN MATEO, Calif., June 13, 2018 (GLOBE NEWSWIRE) -- Cloudian, the innovation leader in enterprise object storage systems, today announced the appointment of Hamed Fadel as vice president customer success. Fadel, who will report to CEO Michael Tso, will lead support and technical account management for Cloudian, already an acknowledged leader in customer satisfaction.
Fadel, who held the role of vice president of customer success at Siemens Healthineers before moving to Cloudian, brings a strong track record managing large teams and delivering high levels of customer satisfaction in the most demanding of client communities. Fadel spearheaded the digitization of Siemens healthcare customer services through innovations in machine data analytics and machine learning.
Fadel joined Siemens from NetApp, where he served as senior director of global customer quality. Prior to NetApp, Fadel led support and engineering teams at Roche, Genentech, Amgen and IBM.
Fadel holds a doctorate in mechanical engineering from the University of California, Berkeley and dual masters in mechanical engineering and computer integrated manufacturing from UCLA.
"Cloudian has delivered a consistently high level of customer satisfaction, a track record we intend to build on as we grow," said Michael Tso, CEO of Cloudian. "Fadel brings deep technical expertise and a tenacious drive to deliver the best possible customer experience, and we're thrilled to have him at Cloudian to help expand and deepen our customer relationships."
Cloudian's support organization is already recognized as a leader in customer satisfaction, earning more than 97% "satisfied" ratings in customer feedback gathered over the past 30 months.
"My passion is to build support organizations that anticipate our customers' needs, and thereby make every customer interaction a great experience," said Fadel. "The Cloudian team mirrors my passion, and I'm excited to join an organization that is equally dedicated to my goal of ensuring that every Cloudian customer becomes a Cloudian advocate."
About Cloudian
Cloudian turns information into insight with an infinitely scalable platform that consolidates, manages and protects enterprise data. Cloudian data management solutions bring cloud technology and economics to the data center with uncompromising data durability, intuitive management tools, and the industry's most compatible S3 API. Cloudian and its ecosystem partners help Global 1000 customers simplify unstructured data management today, while preparing for the data demands of AI and machine learning tomorrow.
Join us on LinkedIn, follow us on Twitter (@CloudianStorage) and Facebook, or visit us at www.cloudian.com.
Media Contact:
Jordan Tewell
10Fold
cloudian@10Fold.com
415-800-5385
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0c2916a5-303d-401c-a974-03cf069b9c78
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cloudian via Globenewswire
About GlobeNewswire
GlobeNewswireGlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Corline Biomedical AB presenterar på Redeyes Temaevent Orphan Drugs26.5.2020 13:49:07 CEST | Pressemelding
Corline Biomedical AB (”Corline”) kommer att presentera sin verksamhet på Redeyes temaevent Orphan Drugs. Presentationen sker kl 11:30 den 27 maj 2020 i Stockholm och livesänds via Redeyes hemsida. Konferensprogrammet och livesändningen görs tillgängliga via Redeyes hemsida https://www.redeye.se/live/orphan-27-maj. För mer information, vänligen kontakta Henrik Nittmar, VD Telefon: 018-71 30 90 E-post: henrik.nittmar@corline.se Certified Adviser Svensk Kapitalmarknadsgranskning Telefon: 011-32 30 732 E-post: ca@skmg.se Corline Biomedical AB arbetar med den kroppsegna substansen heparin och har utvecklat en portfölj med läkemedelskandidater för användning i anslutning till organ- och celltransplantation. Bolaget planerar kliniska studier inom diabetes typ 1 och njurtransplantation, för vilket Corline även har erhållit särläkemedelsstatus (”Orphan Drug”). Inom ramen för helägda dotterbolaget Corline Pharma AB utvärderas in vivo-administration av Corlines heparinsubstans och sedan tidigare
Lundin Gold Inc. Announces C$50 Million Bought Deal Financing26.5.2020 13:30:02 CEST | Press release
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION TO UNITED STATES VANCOUVER, British Columbia, May 26, 2020 (GLOBE NEWSWIRE) -- Lundin Gold Inc. ("Lundin Gold" or the "Company") (TSX: LUG, Nasdaq Stockholm: LUG) has announced today that it has entered into an agreement with BMO Capital Markets (“BMO”), under which BMO has agreed to buy on a bought deal basis 4,150,000 common shares (the “Common Shares”), at a price of C$12.05 per Common Share for gross proceeds of approximately C$50 million (the “Offering”). The Company has granted BMO an option, exercisable at the offering price for a period of 30 days following the closing of the Offering, to purchase up to an additional 15% of the Offering to cover over-allotments, if any. The offering is expected to close on or about June 11, 2020 and is subject to Lundin Gold receiving all necessary regulatory approvals. Newcrest Mining Limited, which currently holds approximately 32% of the Company’s issued and outsta
PCI Biotech: Disclosure of voting rights for Chairman of the Board26.5.2020 13:20:03 CEST | Press release
Oslo, 26 May 2020. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall open the annual general meeting of the Company on 27 May 2020. Mr. Bøhn holds 123,662 shares, representing 0.3 per cent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 7,171,710 additional shares. In total, Mr. Bøhn will represent and vote for 19.6 per cent of the share capital. A major part of the powers of attorney are without voting instructions. The powers of attorney are only valid at the annual general meeting on 27 May 2020. This information is subject to the disclosure requirements pursuant to section 4 -3, cf. section 5-12 of the Norwegian Securities Trading Act. Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 9400 5757
Prosafe SE: First quarter 2020 report – Adapting to a new reality26.5.2020 11:44:38 CEST | Press release
(Figures in brackets refer to the corresponding period of 2019) After several years of low activity across the industry, the company has presented a business plan and a restructuring proposal to lenders which – if approved as proposed – will result in a sustainable balance sheet. The revised business plan reflects a new reality in light of Covid-19, structural changes, oil price collapse, oversupply and anticipated impact on future activity and performance. Consequently, an impairment of USD 810.5 million was made to the book value of vessels in the quarter resulting in a negative book equity of USD 858.9 million by the end of the quarter. The company has sufficient liquidity of USD 184 million at the end of the quarter and continues to operate on a going concern basis on the assumption that there is justified hope to agree a sustainable financial solution with lenders. Recent highlights Prosafe implemented Covid-19 plans early to safeguard people and assets, and this has proven succes
Result of Riksbank reversed auctions SEK Municipal Bonds26.5.2020 11:30:00 CEST | Press release
Result of Riksbank reversed auctions SEK Municipal Bonds Results of auctions Municipal BondsAggregateAuction date5/26/2020Maturity2022Tendered volume, mln SEK750 +/- 750Volume offered, mln SEK1,600Volume bought, mln SEK100Number of bids4Number of accepted bids1Credit Class 1Maturity, QuarterQ1Maturity, QuarterQ2Maturity, QuarterQ3Maturity, QuarterQ4Volume Offered, mln SEK0Volume Offered, mln SEK0Volume Offered, mln SEK0Volume Offered, mln SEK0Volume bought, mln SEK0Volume bought, mln SEK0Volume bought, mln SEK0Volume bought, mln SEK0Number of bids0Number of bids0Number of bids0Number of bids0Number of accepted bids0Number of accepted bids0Number of accepted bids0Number of accepted bids0Average yield-Average yield-Average yield-Average yield-Lowest accepted yield-Lowest accepted yield-Lowest accepted yield-Lowest accepted yield-Highest yield-Highest yield-Highest yield-Highest yield-% accepted at lowest yield-% accepted at lowest yield-% accepted at lowest yield-% accepted at lowest yie
Result of Riksbank certificate sale26.5.2020 10:15:00 CEST | Press release
CERTIFICATE MATURITY200603 FIXED RATE0.00 %OFFERED VOLUME380.000 BLNTOTAL BID AMOUNT1322.350 BLNACCEPTED VOLUME 380.000 BLN PERCENTAGE ALLOTTED 28.7370 %NUMBER OF BIDS14 DEPOSIT RATE-0.10 %LENDING RATE0.20 %